Tofacitinib for RA Misses the Mark in Safety Study ...Middle East

News by : (Medscape) -
Daily treatment with tofacitinib led to more malignancies and adverse cardiovascular events in older rheumatoid arthritis patients compared with treatment with a tumor necrosis factor inhibitor. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Tofacitinib for RA Misses the Mark in Safety Study )

Also on site :

Most Viewed News
جديد الاخبار